RegeneRx Biopharmaceuticals, Inc. And Digital Aria Sign Product License And Stock Purchase Agreements

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX) (“the Company” or “RegeneRx”) today announced that it has entered into two product license agreements with Digital Aria Co., Ltd., headquartered in Gyeonggi-do, Korea, for Digital Aria to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. Digital Aria will also make an equity investment into RegeneRx of $2.35 million enabling RegeneRx to move forward with its ophthalmic clinical program, and retains a 10-month option to purchase additional common stock for $825,000.

Help employers find you! Check out all the jobs and post your resume.